BellBrook Labs Seeking Partners to Accelerate Commercialization of Innovative HTS Assay Technologies

BellBrook Labs, an innovative developer of drug discovery tools, is seeking partners for the development of advanced tools for cellular and biochemical HTS assays using the company’s iuvo™ microchannel array platform and Transcreener® HTS enzyme assay platform. Licensing, distribution and co-development opportunities are available in applications including chemotaxis assays, invasion assays, and assays for GPCR related targets.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Madison, WI (PRWEB) November 20, 2013

BellBrook labs, an innovative developer of drug discovery tools, is seeking out collaborative scientific and commercial partners in cases where further development or commercialization of a technology is outside of the company’s core capabilities. The company develops technologies for both cellular and biochemical HTS assays. The company’s iuvo™ microchannel array platform, developed with expert engineering, microfluidic and microfabrication capabilities, is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology. The company’s Transcreener® HTS enzyme assays rely on proprietary immunodetection reagents to enable screening of thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The partnering portfolio includes cutting-edge drug discovery tools for chemotaxis assays, invasion assays, and assays for GPCR related targets. Two examples of technologies available for partnering are described below and detailed descriptions of the entire portfolio are available on BellBrook’s new Partnering webpage.

The CellWasher Plate is a multiwell plate with proprietary modifications to the wells that protect cells from liquid flow and enable the use of full immunocytochemistry protocols and other assays with multiple wash steps with greater than 90% retention of even the most non-adherent cells. Prototypes have been tested at Pharma and life science research companies, and are ready for final design optimization and full scale manufacturing.

BellBrook’s RGScreen assay is the only HTS -ready assay method for measuring Regulaor of G Protein Signaling (RGS) protein catalytic activity. The most direct way to detect RGS function is by measuring the increased GTPase activity of the associated Galpha protein. However, the GTPase activity of isolated Galpha proteins is limited by GDP dissociation, so RGS GAP activity cannot be measured using simple biochemical assays. Bellbrook’s novel RGScreen™ platform overcomes this kinetic constraint by using proprietary Galpha protein variants with altered GTP hydrolysis and GDP dissociation rates that enable detection of RGS GAP activity using the Transcreener® GDP Assay.

About BellBrook Labs. BellBrook Labs is a private, R&D driven company dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s products, including Transcreener® HTS enzyme assays and iuvo™ Microconduit Array plates are used by all of the major pharmaceutical companies and are available directly from BellBrook Labs or from their international distribution partners. For more information on any of these technologies or to discuss partnering opportunities, contact BellBrook Labs: @info.bellbrooklabs.com.


Contact